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Abstract 
Purpose: To investigate the effect of lipoxin A4 (LXA4) on the expressions of protein and mRNA of 
alveolar epithelial sodium channel (ENaC) in normal and lipopolysaccharide (LPS)-stimulated A549 
cells. 
Methods: A549 cell-lines were randomized into 11 groups (N = 8) and treated. EnaC level was 
evaluated by Western blot. Total RNA was extracted and reverse-transcribed and then levels of ENaC 
mRNA, cGMP and cAMP in the cells were determined. 
Results: LXA4 (10-7mol/L) increased the expressions of α-subunit of ENaC relative to LPS group. In 
addition, LXA4 significantly up-regulated the expression of mRNAs of α, β and γ subunits of ENaC (p < 
0.01). The level of cAMP was increased in LXA4 group, but significantly reduced in LPS group relative 
to control group (p < 0.05).  However, treatment with LXA4 annulled the increased cAMP concentration, 
compared with LPS group (p < 0.05) 
Conclusion: These results show that LXA4 influences ENaC up-regulation in normal and LPS 
stimulated A549 alveolar epithelial cells. 
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Acute lung injury (ALI) and acute respiratory 
distress syndrome (ARDS) lead to respiratory 
failure and pulmonary edema [1]. Alveolar 
epithelial injury is a major contributor to alveolar 
flooding. Injury to alveolar epithelium prevents re-
absorption of edema fluid, a key step in the 
resolution of ALI/ARDS [1,2]. Earlier studies 
showed that alveolar epithelial sodium channel 
(ENaC) and Na-K-ATPase play critical roles in 
reducing edema in ALI/ARDS [3,4]. 
 
Lipoxins (LXs), as anti-inflammatory and pro-
resolution mediators, have been extensively 
studied in various inflammatory diseases, as well 
as their interactions with lipoxin A4 (LXA4) 
receptors [5,6]. These receptors includde LXR 
(lipoxin receptor), cysLT1 (cysteinyl leukotriene 
receptor 1), cysLT2 (cysteinyl leukotriene 
receptor 2) and AhR (aromatic hydrocarbon 
receptor) [7]. Previous studies have 
demonstrated that post-treatment with LXA4 
significantly reduced ALI in LPS-stimulated mice 
[8]. A recent report showed that LXA4 improved 
ENaC expression through ALX–cGMP signaling 
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pathways, resulting in enhanced clearance of 
alveolar fluid in oleic acid-stimulated animals [9]. 
 
The present study aims to test the hypothesis 
that LXA4 increases ENaC protein and mRNA 
expressions in normal and LPS-stimulated A549 
cells. In addition, it investigated LXA4 receptors, 
ALX, AhR, cysLRT1 and cysLRT2 to determine 
the key receptors involved in up-regulation of 
ENaC function in A549 cells, as well as the levels 






Lipopolysaccharide (LPS; E. coil serotype 055: 
B5) and AhR inhibitor, α-naphthoflavone (ANF) 
were purchased from Sigma (St. Louis, MO). 
Lipoxin A4 was obtained from Cayman Chemical 
Company (Ann Arbor, MI). CysLT2 receptor 
inhibitor, BAY-u9773 was from Bimol Company 
(Farmingdale, NY). RPMI Medium 1640 and FCS 
were purchased from Gibco (Grand Island, NY). 
Saline citrate-buffered streptomycin and penicillin 
were products of Invitrogen (CA). The α, β and γ 
subunits of anti- ENaC were products of Abcam 
Company (Cambridge, MA), while anti-β-actin 
was supplied by Santa Cruz Company (Santa 
Cruz, CA). ELISA kits for cAMP and cGMP were 
purchased from R&D systems (Minneapolis, 
MN). Rp-cAMP (cAMP inhibitor) was obtained 
from Biomol-Enzo Life Sciences (Farmingdale, 
NY), while BCA protein assay kits and RT-PCR 
kits were purchased from Thermo Scientific 
(Rockford, IL). Real-time PCR Master Mix (SYBR 
Green) was obtained from Toyobo (Japan). 
 
Cell culture and treatment  
 
Human epithelial cell line (A549 cell line) was 
obtained from Basic Medical Sciences of 
Zhejiang Wenzhou Medical University. The cell 
line was cultured at 37 °C in a 5 % CO2 
humidified atmosphere, in RPMI 1640 medium 
containing 10 % fetal calf serum (FCS), 100 U/ml 
penicillin G and 100 μg/mL streptomycin.. The 
cells were sub-cultured into six-well plates to 80 
% sub-confluence; 100 % confluent cells were 
maintained for 24h in low serum medium (PRMI 
containing 0.1 % FCS). Thereafter, the cells were 
randomized into eleven groups (n = 8): control, 
LPS (1 µg/mL), LPS + ethanol (3.7 μl/mL), LPS + 
LXA4 (10-9 M), LPS + LXA4 (10-8 M), LPS + LXA4 
(10-7 M), LPS + LXA4 (10-6 M), LXA4 (10-7 M), 
ethanol, LXA4 (10-7 M)  +  BAY-u9773 (3 μM ) 
and LXA4 (10-7 M)  + ANF (1 nM) groups. In each 
group, the reagents were added simultaneously 
to stimulated cells and incubated for 6, 12 and 24 
h. At the end of incubation, the cells were 
harvested and subjected to sonication. 
 
Western blot for α, β and γ subunits of EnaC 
 
Samples were lysed in standard RIPA lysis 
solution composed of 50 mM Tris buffer, pH 7.4, 
150 mM NaCl, 1 % Triton X-100, 1 % sodium 
deoxycholate, 0.1 % SDS, 4 mM sodium 
pyrophosphate, 5 mM sodium fluoride, 1 mM 
EDTA, 0.02 mM leupeptin and 1mM 
phenylmethyl sulfonylfluoride (PMSF) on ice for 
30 min, and thereafter centrifuged for 10 min at 
12,000 rpm. The protein contents of the 
supernatants were estimated using BCA protein 
assay kitx. The protein mixture from the 
supernatants (80 µg) were separately boiled to 
achieve denaturation, and then subjected to 
10 % SDS-PAGE prior to transfer onto PVDF 
membranes. Following blocking for 2 h with 5% 
non-fat dry milk in TBS-T buffer, expression of 
the α subunit of ENaC was determined using 
primary anti-epithelial sodium channel alpha 
antibody (1:750). The expression of the β subunit 
was determined using primary anti-SCNN1B 
antibody (1:500), while the expression of γ 
subunit was measured using primary anti-
epithelial sodium channel gamma antibody 
(1:1000), and secondary goat anti-rabbit IgG. β-
actin was used as internal control. Detection of 
the bound antibody was carried out on X-ray 
films by enhanced chemiluminescence (ECL). 
 
RNA isolation, reverse transcriptase and PCR 
 
Total RNA was extracted using Trizol reagent 
according to manufacturer’s protocol. One (1) 
microgram of RNA sample was reverse-
transcribed into complementary DNA (cDNA) 
using a RT-PCR kit on the MJ Mini Thermal 
Cycler (Bio-Rad, Hercules, CA, USA), according 
to the manufacturer's instructions. The primer 
sequences used for PCR amplification are in 
Table 1.  
 
Then semi-quantitative analysis was performed 
by UVP-gel densitometry. 
 
Quantitative real-time PCR 
 
Levels of ENaC mRNA in A549 cells were 
determined with SYBR Prime Script Kit on the 
CFX96 Real-Time PCR Detection System (Bio-
Rad, Hercules, CA, USA). Primers used for 
amplification are in Table 2. 
 
Data was analyzed as previously described [9] 
using GAPDH as a reference gene. 
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Table 1: Primer sequence 
 
Gene Sequence length (bp) Primer sequence 
ALX 173 5’-TCCATTGTTGCCATCTGCTAT-3’ (sense) 5’-AACATCTCT TTGAGCCAGACG-3’(antisense); 
AhR 469 5’-TTAACGGATGAAATCCTGACG-3’ (sense) 5’-AAGTAGTGGGGTATGGGGATG-3’ (antisense) 
CysLTR1 437 5’-GCCAGGTTTGTGTGTGTAGGT-3’ (sense) 5’- GCAGCCAGAGACAAGGTTATG -3’ (antisense); 
CysLTR2 222 5’-TTGTGTTTCCTGCCCTATCAC-3’(sense) 5’-CTTTGTCTTTGCCTTCTGTGG-3’ (antisense); 
β-actin 204 5’-CCTTCCTGGGCATGGAGTCCT-3’ (sense) 5’-GGAGCAATGATCTTGATCTT-3’ (antisense). 
 
Table 2: Primers for amplification 
 
Variable Sense Antisense 
α-ENaC 5’-CAGCCCATACCAGGTCTCAT-3’ 5’- ATGGTGGTGTTGTTGCAGAA-3’ 
β-ENaC 5’- ATGGTGGTGTTGTTGCAGAA-3’ 5’- CCAGGAAGGAGAAAACCACA-3’ 
γ-ENaC 5’- ACCACCAGCCATGGTCTAAG-3’ 5’- GTTCAGGTCCCGGGATTTAT-3’ 
GAPDH 5’- GAGTCAACGGATTTGGTCGT-3’ 5’-TTGATTTTGGAGGGATCTCG-3’ 
 
cAMP and cGMP assays 
 
A549 cells were prepared, plated into six-well 
plates at a density 105/well and maintained sub-
confluent (80 %). Confluent cells (100 %) were 
maintained for 24 h in serum-free medium, then 
treated with LPS (1 μg/ml), LXA4 (10-7 M), BAY-
u9773 (3 μM ) or ANF (1 nM) for 24 h. The 
supernatants recovered after centrifugation were 





Data are expressed as mean ± SEM, and groups 
were compared by one-way ANOVA followed by 
Newman-Keuls multiple inter-group comparisons, 
using SPSS version 16.0 software. A probability 




Dose-dependency of LXA4 regulated ENaC 
expression in A549 cells stimulated with LPS 
 
In all responses, only 10-7 M LXA4 increased 
ENaC α subunit expression when compared with 
LPS group (Figure 1A). However, the 
expressions of the β and γ subunits of ENaC 
were increased dose-dependently, peaking at 10-
7 M LXA4 (Figure 1B and C). Therefore, in 
subsequent experiments, the expression of 
ENaC in A549 cells treated with LPS was 
assessed using 10-7 M LXA4. 
 
Time-dependency of LXA4 regulated ENaC 
expression in A549 cells stimulated with LPS 
 
At 6 h, LPS significantly decreased the 
expressions of α, β and γ subunits of ENaC 
when compared with control group (p < 0.01); 
while LXA4 significantly increased the 
expressions of these subunits, compared with 
control group (p < 0.01; Figure 2). At 12 h, the 
protein levels of the α, β and γ subunits were 
decreased in the LPS group, but elevated in the 
LPS + LXA4 group relative to the LPS group (p < 
0.05; Figure 3). At 24 h, the levels of the α, β and 
γ subunits of ENaC were significantly decreased 
in the LPS group, but increased in the LPS + 
LXA4 group when compared with the LPS group 
(p < 0.01; Figure 4). Therefore, in subsequent 
experiments, the effect of LXA4 on ENaC 
expression in LPS-stimulated A549 cells was 
assessed at 24 h. 
 
Effect of LXA4 on the ENaC mRNA expression 
in A549 cells stimulated with LPS 
 
The cells were incubated with LPS (1μg/mL) with 
or without LXA4 (10-7 M) for 6 h. It was found that 
LXA4 significantly up-regulated the expressions 
of mRNAs of α, β and γ subunits of ENaC (p < 
0.01), and LPS decreased the mRNA level of 
ENaC α subunit relative to the control group (p < 
0.05; Figure 5A). However, no significant change 
in mRNA expression of β and γ subunits was 
observed (p > 0.05; Figure 5B and C). 
Interestingly, the expressions of mRNAs of the β 
and γ subunits of ENaC were increased in LPS + 
LXA4 group when compared with LPS group (p < 
0.05), but not the ENaC α subunit. 
 
Receptors of LXA4 on A549 cells 
 
As shown in Figure 6, LXA4 receptor cysLT2 and 
AhR mRNA were expressed in A549 cells. 
However, cysLT1 and LXR mRNA were not 
expressed in A549 cells. 
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Figure 1: Effect of different concentrations of LXA4 on the expressions of the α, β and γ subunits of 
ENaC after 24h in LPS-treated A549 cells. A549 cells were treated with LXA4 (10-6, 10-7, 10-8, 10-9 M) 
in the presence of LPS (1 μg/mL) for 24 h. Cells were then harvested, and sonicated. ENaCα (A), β 
(B) and γ (C) subunits protein were measured by western blotting. Results are presented as mean ± 
SEM for each group. *p < 0.05, **p < 0.01 compared to control group, #p < 0.05, ##p < 0.01 relative to 




Figure 2: Effect of LXA4 on ENaC α, β and γ subunits protein expression at 6 h in LPS-induced A549 
cells. A549 cells were treated with LXA4 (10-7 M) in the presence or absence of LPS (1 μg/ml) for 6 h. 
Cells were then harvested, and sonicated. ENaCα (A, D, G), β (B, E, H) and γ (C, F, I) protein 
expressions at 6 h were determined by western blotting. Data are expressed as mean ± SEM for each 
group. *p < 0.05, **p < 0.01 versus Control group, #p < 0.05, ##p < 0.01 versus LPS group, $p < 0.05, 
$$p < 0.01 versus Ethanol group (n = 4). Ethanol is resolvent 
 
 
Figure 3: Effect of LXA4 on ENaCα, β and γ subunits protein expression at 12 h in LPS-induced A549 
cells. A549 cells were treated with LXA4 (10-7 M) in the presence or absence of LPS (1 μg/ml) for 12 h. 
Cells were then harvested, and sonicated. ENaCα (A, D, G), β (B, E, H) and γ (C, F, I) protein 
expressions at 12 h were determined by western blotting. Data are expressed as mean ± SEM for 
each group. *p < 0.05, **p < 0.01 versus Control group, #p < 0.05, ##p < 0.01 versus LPS group, $p < 
0.05, $$p < 0.01 versus Ethanol group (n = 4). Ethanol is resolvent 
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Figure 4: Effect of LXA4 on expressions of α, β and γ subunits of ENaC at 24 h in LPS-induced A549 cells. A549 
cells were exposed to LXA4 (10-7 M) in the presence or absence of LPS (1 μg/ml) for 24 h. The cells were then 
harvested, and sonicated. ENaCα (A, D, G), β (B, E, H) and γ (C, F, I) protein expression at 24 h were 
determined using western blotting. Data are expressed as mean ± SEM for each group. *p < 0.05, **p < 0.01 
versus Control group, #p < 0.05, ##p < 0.01 versus LPS group, $p < 0.05, $$p < 0.01 versus Ethanol group (n = 4); 
ethanol was resolvent 
 
 
Figure 5: The effect of LXA4 on the expressions of mRNAs of the α, β and γ subunits of ENaC at 6h in LPS-
induced A549 cells. A549 cells were treated with LXA4 (10-7 M) in the presence and absence of LPS (1 μg/ml). 
After incubating for 6 h, the ENaC α (A), β (B), and γ (C) subunits mRNA expressions were determined by real-
time PCR. Data are expressed as mean ± SEM for each group. *p < 0.05, **p < 0.01 versus control group, #p < 
0.05, ##p < 0.01 versus LPS group, $p < 0.05, $$p < 0.01 versus Ethanol group (n = 8). Ethanol was resolvent. 
 
 
Figure 6: The expression of LXA4 receptors in 
A549 cells. A549 cells were treated with LXA4 
(10-7 M) for 24h. After incubation, the cells were 
harvested and sonicated. ALX (lipoxin receptor), 
AhR (aromatic hydrocarbon receptor), cysLRT1 
(cysteinylLT1 receptor) and cysLRT2 
(cysteinylLT2 receptor) were determined by 
reverse transcriptase-polymerase chain reaction 
(n = 8). 
 
Effect of LXA4 receptors on expression of 
ENaC protein in A549 cells following LPS 
exposure 
 
Protein expressions of the α、β and γ subunits of 
ENaC were up-regulated by LXA4, but were 
blocked by the LXA4 receptor inhibitor, ANF. 
However, BAY-u9773 was not inhibitory (Figure 
7). 
 
LXA4 promoted ENaC expression  
 
To test whether LXA4 (10-7 M) had an impact on 
cAMP and cGMP levels in A549 cells, we 
measured cAMP and cGMP concentration in 
A549 cells exposed to LPS (1 μg/mL) for 24 h by 
ELISA kits. It was found that cAMP concentration 
was increased in the LXA4 group, but was 
reduced in the LPS group relative to control 
group (p< 0.05). , and treatment with LXA4 
reversed the increased cAMP concentration 
when compared with the LPS group (p < 0.05; 
Figure 8A). In addition, when BAY-u9773 (cysLT2  
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Figure 7: The effect of LXA4 receptor antagonists on protein expression of ENaC in LXA4 (10-7 M)-treated A549 
cells. A549 cells were exposed to LXA4 for 24 h in the presence of either BAY-u9733 (cysLRT2 antagonist, 3 μM) 
or ANF (AhR antagonist, 1 nM). After harvesting the cells and sonicating them, the protein expressions of the α 
(A), β (B) and γ (C) subunits of ENaC were determined by western blotting. Data are mean ± SEM. *p < 0.05, **p 




Figure 8: Effect of LXA4 and LXA4 receptor antagonists on cAMP and cGMP in A549 cells. A549 cells were 
treated with LXA4 (10-7M) in the presence and absence of LPS (1 μg/mL), BAY-u9773 (cysLRT2 antagonist, 3 μM) 
or ANF (AhR antagonist, 1 nM) for 24 h. cAMP (A) and cGMP (B) protein concentration of suspension were 
determined by ELISA kits. Data are expressed as mean ± SEM for each group. *p < 0.05, **p < 0.01 versus 
control group, #p < 0.05, ##p < 0.01 versus LPS group, $p < 0.05, $$p < 0.01 versus Ethanol group, &p < 0.05 
versus LXA4 group (n = 8). Ethanol was resolvent 
 
antagonist, 3 μM) and ANF (AhR antagonist, 
1nM) were used to treat A549 cells in the 
presence of LXA4 for 24 h, cAMP concentration 
was decreased in the LXA4 + ANF group relative 
to the LXA4 group (p < 0.05), but not in the LXA4 
+  BAY-u9773 group (Figure 8C). However, no 
significant change was seen in cGMP levels in 
these groups (Figure 8B & Figure 8D). 
 
The protein levels of α, β and γ subunits were 
markedly decreased in LPS + LXA4 + Rp-cAMP 





ALI/ARDS is a common, devastating clinical 
syndrome that affects large numbers of patients 
and has up to 40 % mortality [10]. The current 
treatment for ALI/ARDS is aimed at removal of 
polymorphonuclear neutrophils, and alveolar fluid 
re-absorption. Cation and anion channels and ion 
transporters are involved in the clearance of 
alveolar fluid. Several studies have reported the 
key role of ENAC not only in the uptake of Na+ 
from the alveolar fluid but also in the clearance of 
the fluid itself [2,3,11-13]. In the present study, it 
has been clearly demonstrated that LXA4 up-
regulated the expressions of the mRNAs and 
proteins of the α, β and γ subunits of ENAC in 
normal and LPS-treated human alveolar 
epithelial cells. These up-regulations were both 
dose- and time-dependent. These effects were 
blocked by the inhibitor of AhR and Rp-cAMP, an
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Figure 9: LXA4 increased ENaC expression dependent on cAMP in A549 cells stimulated with LPS. Cells were 
treated with RP-cAMP (cAMP inhibitor, 10 uM) in the presence of LXA4 (10-7 M) and LPS (1 ug/mL) for 24 h. After 
incubation, the cells were harvested, and sonicated. ENaC α, β and γ subunits protein expression in the cell 
lysates were determined by western blotting using a specific antibody 
 
indication that LXA4 enhanced the expression of 
ENaC through AhR-cAMP signaling pathway. 
 
The expressions of the mRNAs and proteins of 
the α, β and γ subunits of ENAC were decreased 
by 1μg/mL LPS, but these decreases were dose-
dependently reversed by LXA4,  with maximal 
effect at 10-7 M. These findings are in 
disagreement with recent reports which suggest 
that LXA4 enhanced the expression of ENaC in 
A549 alveolar cells [10]. Interestingly, it was 
found that 10-6 M LXA4 was less effective than 
10-7 M. This implies that the effect of LXA4 was 
not concentration-dependent. It is also likely that 
at 10-6 M, LXA4 actually brought about decreased 
expression of ENaC. Thus, 10-6 M LXA4 was 
used in subsequent experiments. LXA4 
significantly improved the expressions of the α, β 
and γ subunits of ENAC in healthy A549 cells 
and in LPS-treated cells at 6, 12 and 24 h. The 
expressions in the LPS group at 24 h were much 
lower than those at 6 h and 12 h, suggesting a 
greater degree of cellular damage at 24 h than at 
any of the other periods. It has been reported 
that LXA4 increased ENaC concentrations in 
primary rat alveolar type II epithelial cells 
exposed to LPS 24 h [21]. Therefore, in 
subsequent studies, the effect of LXA4 on ENaC 
expression in LPS-treated A549 cells was 
evaluated at 24 h. The results obtained in the 
present study show that LXA4 regulates the 
expression of ENaC in healthy and pathological 
states. This is consistent with previous results 
which suggest that LXA4 may be involved in 
endotoxin-induced ALI/ARDS [14].  
 
The expression of the mRNA of the α subunit of 
ENAC was decreased following exposure to 1 
μg/mL LPS for 6 h, but there were no significant 
changes in the expressions of mRNAs for the β 
and γ subunits. This shows that the expression of 
mRNA of the sodium channel was inhibited by 
LPS. In a previous study, it was reported that 
mouse alveolar epithelial cells treated with LPS 
for 8 h had significantly reduced expressions of 
mRNAs for the α, β and γ subunits of ENAC [27]. 
The fact that LXA4 increased mRNA expressions 
for α, β and γ of ENAC at 6 h indicates that LXA4 
protected the cells by enhancing ENaC gene 
translation.   
 
LXs mediate their effects by interacting with one 
or more specific receptors such as ALX, 
CysLTR1, CysLTR2 and AhR. In this study, 
CysLTR2 and AhR were the only receptors 
present on the basolateral membrane of the 
A549 cells, which is consistent with previous 
findings showing that A549 cells expressed 
mRNAs of cysLT2 and AhR only [16-18]. The 
beneficial effects of LXA4 were reversed by ANF, 
an AhR antagonist, but not by the cysLT2 
receptor antagonist BAY-u9773. This is clear 
evidence that the effect of LXA4 on expression of 
the α, β and γ subunits of ENAC occurred 
through binding to AhR.  
 
cAMP and cGMP are important second 
messengers by which cells transduce 
extracellular signals into intracellular responses. 
Extracellular signals interact with GPCRs to 
activate adenylate cyclase (AC) and increase 
intracellular cAMP levels. A previous study 
showed that LPS-induced immune responses are 
associated with decreases in intracellular cAMP 
levels [7]. It has been reported that LPS activates 
inhibitory G protein, thereby inhibiting formation 
of cAMP [19]. Stimulation by cAMP enhances 
Na+ transport and the activity of Na-K-ATPase in 
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the plasma membrane [20, 21]. This is in 
agreement with a model that suggests that at the 
early stages, cAMP enhances the transport of 
ENaC to the cell surface, whereas the synthesis 
of ENaC is necessary for the sustenance  of this 
effect [20]. Extracellular signals also interact with 
GPCR to activate guanylyl cyclases (GC) and 
increase intracellular cGMP levels. Studies have 
shown that AhR induces signaling pathways that 
entail ERK, PKA, MMP9 and cAMP, cGMP and 
Ca2+ [22]. It has also been shown that AhR is 
more sensitive to the cAMP signaling pathway 
[22,23], and that cAMP induces nuclear 
translocation of the AhR [24]. Thus it appears 
that the two signaling pathways for regulation of 
ENaC, cAMP, and cGMP are compart-
mentalized. Levels of intracellular cAMP were 
decreased after LPS stimulation, and the 
decreases were reversed by LXA4 in the LPS 
group. The reversal of the effects of LXA4 by 
ANF and Rp-cAMP, without any significant 
effects on intracellular cGMP levels indicates that 
LXA4 increases the levels of cAMP through AhR. 
Thus LXA4 up-regulates the expressions of α, β 
and γ subunits of ENaC by activating cAMP via 
AhR. The role of LXA4 in LPS-treated human 
alveolar epithelial cells can be depicted as 
indicated in Figure 10. 
 
 
Figure 10: Modulation of sodium channel in 





This study has provided evidence for up-
regulation of ENAC in normal and LP-stimulated 
A549 alveolar epithelial cells, most probably 
through the AhR–cAMP signaling pathways. 
Thus, it is proposed that LXA4 can be applied for 
the induction of ENaC expression in the 
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